KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 176,647 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $7.21, for a total transaction of $1,273,624.87. Following the sale, the insider now owns 2,876,027 shares in the company, valued at $20,736,154.67. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $8.05, for a total transaction of $80,500.00.
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $8.02, for a total transaction of $207,718.00.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ KALV) traded down 13.11% during mid-day trading on Friday, hitting $6.96. 162,624 shares of the stock traded hands. The stock’s market cap is $67.60 million. The firm has a 50 day moving average of $8.20 and a 200 day moving average of $7.83. KalVista Pharmaceuticals, Inc. has a 12 month low of $6.09 and a 12 month high of $10.65.
KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 57.41%. The firm had revenue of $0.10 million for the quarter. On average, equities analysts expect that KalVista Pharmaceuticals, Inc. will post ($2.94) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/16/kalvista-pharmaceuticals-inc-kalv-major-shareholder-holdings-as-novo-sells-176647-shares-of-stock.html.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned approximately 1.01% of KalVista Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 75.66% of the stock is currently owned by hedge funds and other institutional investors.
KALV has been the topic of several recent analyst reports. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a research report on Thursday, August 31st. They set a “buy” rating and a $18.00 price objective on the stock. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 2nd.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.